- Home
- AGAE vs INTS Comparison
AGAE vs INTS Comparison
Compare AGAE & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGAE
- INTS
- Stock Information
- Founded
- AGAE 2017
- INTS 2012
- Country
- AGAE United States
- INTS United States
- Employees
- AGAE N/A
- INTS N/A
- Industry
- AGAE Cable & Other Pay Television Services
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- AGAE Telecommunications
- INTS Health Care
- Exchange
- AGAE Nasdaq
- INTS Nasdaq
- Market Cap
- AGAE 115.6M
- INTS 8.0M
- IPO Year
- AGAE N/A
- INTS 2023
- Fundamental
- Price
- AGAE $1.63
- INTS $0.33
- Analyst Decision
- AGAE
- INTS Strong Buy
- Analyst Count
- AGAE 0
- INTS 3
- Target Price
- AGAE N/A
- INTS $8.50
- AVG Volume (30 Days)
- AGAE 126.0K
- INTS 3.7M
- Earning Date
- AGAE 07-07-2025
- INTS 08-07-2025
- Dividend Yield
- AGAE N/A
- INTS N/A
- EPS Growth
- AGAE N/A
- INTS N/A
- EPS
- AGAE N/A
- INTS N/A
- Revenue
- AGAE $8,975,246.00
- INTS N/A
- Revenue This Year
- AGAE N/A
- INTS N/A
- Revenue Next Year
- AGAE N/A
- INTS N/A
- P/E Ratio
- AGAE N/A
- INTS N/A
- Revenue Growth
- AGAE 1.52
- INTS N/A
- 52 Week Low
- AGAE $0.70
- INTS $0.26
- 52 Week High
- AGAE $3.79
- INTS $5.10
- Technical
- Relative Strength Index (RSI)
- AGAE 36.59
- INTS 41.29
- Support Level
- AGAE $1.67
- INTS $0.26
- Resistance Level
- AGAE $1.80
- INTS $0.32
- Average True Range (ATR)
- AGAE 0.28
- INTS 0.03
- MACD
- AGAE -0.16
- INTS 0.02
- Stochastic Oscillator
- AGAE 0.59
- INTS 62.56
About AGAE Allied Gaming & Entertainment Inc.
Allied Gaming & Entertainment Inc is an experiential entertainment company focused on providing a growing world of gamers with various experiences through renowned assets, products, and services.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.